VTx-002, VTx-002, VTx-002 Diluent clinical trials

Phase 1/2 Investigation Of Novel Experimental Regimen in Amyotrophic Lateral Sclerosis (PIONEER-ALS): An Open-Label, Uncontrolled, Multicenter Study to Assess the Safety and Tolerability of Two Doses of VTx-002.

This study is testing a new experimental treatment for Motor Neurone Disease (ALS) called VTx-002. It's an early-stage trial (Phase 1/2) focused on checking if the treatment is safe and what side effects it might have. Researchers also want to see if it shows any early signs of helping people.